Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joerg Heil

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Cancer Immunology, Immunotherapy : CII|September 15, 2011
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcomeYingzi Ge, Christoph Domschke, Natalija Stoiber, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|May 3, 2014
Recall management of patients with Rofil Medical breast implantsSarah Schott, Thomas Bruckner, Michael Golatta, et al.
Oncotarget|December 30, 2017
Parity improves anti-tumor immunity in breast cancer patientsAnna-Lena Krause, Florian Schuetz, Marc Boudewijns, et al.
Archives of Gynecology and Obstetrics|January 19, 2019
Oncoplastic breast-conserving surgery: More relevant than ever? Results of a survey among breast surgeonsJoerg Heil, Fabian Riedel, Christine Solbach, et al.
Archives of Gynecology and Obstetrics|October 15, 2014
Evaluation of an automated breast 3D-ultrasound system by comparing it with hand-held ultrasound (HHUS) and mammographyMichael Golatta, Christina Baggs, Mirjam Schweitzer-Martin, et al.
Annals of Surgical Oncology|January 7, 2016
Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery?André Hennigs, Valerie Fuchs, Hans-Peter Sinn, et al.
Annals of Surgical Oncology|July 31, 2015
Predictors of Residual Tumor in Breast-Conserving TherapyMichelle G Rath, Lorenz Uhlmann, Joerg Heil, et al.
JCO Clinical Cancer Informatics|December 23, 2024
Machine Learning to Predict the Individual Risk of Treatment-Relevant Toxicity for Patients With Breast Cancer Undergoing Neoadjuvant Systemic TreatmentLie Cai, Thomas M Deutsch, Chris Sidey-Gibbons, et al.
BMC Cancer|June 17, 2011
Simultaneous integrated boost for adjuvant treatment of breast cancer--intensity modulated vs. conventional radiotherapy: the IMRT-MC2 trialVasileios Askoxylakis, Alexandra D Jensen, Matthias F Häfner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?Joerg Heil, Benedikt Schaefgen, Peter Sinn, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Cancer Immunology, Immunotherapy : CII|September 15, 2011
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcomeYingzi Ge, Christoph Domschke, Natalija Stoiber, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|May 3, 2014
Recall management of patients with Rofil Medical breast implantsSarah Schott, Thomas Bruckner, Michael Golatta, et al.
Oncotarget|December 30, 2017
Parity improves anti-tumor immunity in breast cancer patientsAnna-Lena Krause, Florian Schuetz, Marc Boudewijns, et al.
Archives of Gynecology and Obstetrics|January 19, 2019
Oncoplastic breast-conserving surgery: More relevant than ever? Results of a survey among breast surgeonsJoerg Heil, Fabian Riedel, Christine Solbach, et al.
Archives of Gynecology and Obstetrics|October 15, 2014
Evaluation of an automated breast 3D-ultrasound system by comparing it with hand-held ultrasound (HHUS) and mammographyMichael Golatta, Christina Baggs, Mirjam Schweitzer-Martin, et al.
Annals of Surgical Oncology|January 7, 2016
Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery?André Hennigs, Valerie Fuchs, Hans-Peter Sinn, et al.
Annals of Surgical Oncology|July 31, 2015
Predictors of Residual Tumor in Breast-Conserving TherapyMichelle G Rath, Lorenz Uhlmann, Joerg Heil, et al.
JCO Clinical Cancer Informatics|December 23, 2024
Machine Learning to Predict the Individual Risk of Treatment-Relevant Toxicity for Patients With Breast Cancer Undergoing Neoadjuvant Systemic TreatmentLie Cai, Thomas M Deutsch, Chris Sidey-Gibbons, et al.
BMC Cancer|June 17, 2011
Simultaneous integrated boost for adjuvant treatment of breast cancer--intensity modulated vs. conventional radiotherapy: the IMRT-MC2 trialVasileios Askoxylakis, Alexandra D Jensen, Matthias F Häfner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?Joerg Heil, Benedikt Schaefgen, Peter Sinn, et al.
Pageof 10